相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models
Ki Cheong Park et al.
BMC MEDICINE (2023)
Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer
Hyeok Jun Yun et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling
Thomas J. Ettrich et al.
VISCERAL MEDICINE (2022)
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
Amanda J. Kerr et al.
CANCER TREATMENT REVIEWS (2022)
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC
Alex Friedlaender et al.
CANCER TREATMENT REVIEWS (2022)
Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma
Jin Hong Lim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma
Seok-Mo Kim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Targeting oncogenic Notch signaling with SERCA inhibitors
Luca Pagliaro et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Beatriz Henriques et al.
BIOMEDICINES (2021)
The Current Landscape of Clinical Trials for Systemic Treatment of HCC
Friedrich Foerster et al.
CANCERS (2021)
Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook
Ibrahim Halil Sahin et al.
CHINESE CLINICAL ONCOLOGY (2021)
Towards the overcoming of anticancer drug resistance mediated by p53 mutations
Xin Cao et al.
DRUG RESISTANCE UPDATES (2020)
Impact of Age-Related Genetic Differences on the Therapeutic Outcome of Papillary Thyroid Cancer
Seok-Mo Kim et al.
CANCERS (2020)
Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations
Yongkang He
ARCHIV DER PHARMAZIE (2020)
The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer
Carla Colombo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells
Hyung Joon Kim et al.
YONSEI MEDICAL JOURNAL (2020)
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia
Matteo Marchesini et al.
CELL CHEMICAL BIOLOGY (2020)
Targeting cancer stem cell pathways for cancer therapy
Liqun Yang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Exosomal CircPRRX1 Enhances Doxorubicin Resistance in Gastric Cancer by Regulating MiR-3064-5p/PTPN14 Signaling
Shumin Wang et al.
YONSEI MEDICAL JOURNAL (2020)
MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma
Mingpeng Jin et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects
Tihana Ibrahimpasic et al.
THYROID (2019)
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Bryan D. Smith et al.
CANCER CELL (2019)
Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance
Ladan Mashouri et al.
MOLECULAR CANCER (2019)
Cancer cell fusion: a potential target to tackle drug-resistant and metastatic cancer cells
Clara Fernandes et al.
DRUG DISCOVERY TODAY (2019)
Papillary thyroid carcinoma behavior: clues in the tumor microenvironment
Kensey Bergdorf et al.
ENDOCRINE-RELATED CANCER (2019)
Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma
Clifford Akateh et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge
Milica Nedeljkovic et al.
CELLS (2019)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
Jierui Liu et al.
ENDOCRINOLOGY AND METABOLISM (2019)
Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations
Toshinori Ozaki et al.
BMC CANCER (2018)
Cancer stem cell in breast cancer therapeutic resistance
Xupeng Bai et al.
CANCER TREATMENT REVIEWS (2018)
SERCA control of cell death and survival
Elie R. Chemaly et al.
CELL CALCIUM (2018)
The challenge of drug resistance in cancer treatment: a current overview
Michail Nikolaou et al.
CLINICAL & EXPERIMENTAL METASTASIS (2018)
EGFR-TKIs resistance via EGFR-independent signaling pathways
Qian Liu et al.
MOLECULAR CANCER (2018)
The emerging clinical relevance of genomics in cancer medicine
Michael F. Berger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Mechanisms of PARP inhibitor sensitivity and resistance
Alan D. D'Andrea
DNA REPAIR (2018)
Survival of Cancer Stem-Like Cells Under Metabolic Stress via CaMK2 alpha-mediated Upregulation of Sarco/Endoplasmic Reticulum Calcium ATPase Expression
Ki Cheong Park et al.
CLINICAL CANCER RESEARCH (2018)
The role of p53 in cancer drug resistance and targeted chemotherapy
Karin Hientz et al.
ONCOTARGET (2017)
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma
Yasuhiro Ito et al.
THYROID (2017)
Targeting calcium signaling in cancer therapy
Chaochu Cui et al.
ACTA PHARMACEUTICA SINICA B (2017)
Autophagy and multidrug resistance in cancer
Ying-Jie Li et al.
CHINESE JOURNAL OF CANCER (2017)
Curcumin induces apoptosis by inhibiting sarco/endoplasmic reticulum Ca2+ ATPase activity in ovarian cancer cells
Jeong-ah Seo et al.
CANCER LETTERS (2016)
Thyroid Cancer: Risk-Stratified Management and Individualized Therapy
Friedhelm Raue et al.
CLINICAL CANCER RESEARCH (2016)
Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models
Cristina P. R. Xavier et al.
CURRENT CANCER DRUG TARGETS (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Bowen Du et al.
MOLECULES (2016)
Biologic and Clinical Perspectives on Thyroid Cancer
Somayyeh Fahiminiya et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis
Luciana Audi de Castroneves et al.
THYROID (2016)
Resistance of papillary thyroid cancer stem cells to chemotherapy
Raffaella Giuffrida et al.
ONCOLOGY LETTERS (2016)
Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer
Taofeek K. Owonikoko et al.
ONCOLOGIST (2013)
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Robert C. Smallridge et al.
ENDOCRINE-RELATED CANCER (2009)
Calcium Pumps in Health and Disease
Marisa Brini et al.
PHYSIOLOGICAL REVIEWS (2009)
Thyroid carcinoma: molecular pathways and therapeutic targets
Yuri E. Nikiforov
MODERN PATHOLOGY (2008)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors
Jan Willem B. de Groot et al.
ENDOCRINE REVIEWS (2006)
Increasing incidence of thyroid cancer in the United States, 1973-2002
L Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Pathogenetic mechanisms in thyroid follicular-cell neoplasia
T Kondo et al.
NATURE REVIEWS CANCER (2006)
分享论文
